Frankfurt:EII

Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients

Retrieved on: 
水曜日, 3月 6, 2024

By investing in C2N, Eisai seeks to support efforts to advance blood-based Abeta diagnostics that are accurate and affordable, providing new options for confirming the presence of Abeta.

Key Points: 
  • By investing in C2N, Eisai seeks to support efforts to advance blood-based Abeta diagnostics that are accurate and affordable, providing new options for confirming the presence of Abeta.
  • "The field of highly accurate blood-based diagnostics is rapidly advancing and expanding," said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai.
  • "Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem's growth.
  • The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer's disease."

Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050

Retrieved on: 
水曜日, 2月 21, 2024

TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.

Key Points: 
  • TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.
  • Eisai also received approval for the SBT 1.5degC target, a new GHG reduction target, by "Science Based Targets (SBT) initiatives", as outlined below.
  • In order to achieve Net Zero by 2050, Eisai continues to strengthen its GHG reduction initiatives though the JCI Race to Zero Circle and the newly approved SBT 1.5degC target, as well as our continued commitment to the global initiative RE100.
  • Neutralizing any residual emissions at the net-zero target year and any GHG emissions released into the atmosphere thereafter.

Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives

Retrieved on: 
火曜日, 2月 20, 2024

TOKYO, Feb 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.

Key Points: 
  • TOKYO, Feb 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
  • In the "Human Capital Survey 2023" (conducted between September and December 2023), 16 highly rated companies were selected for "Human Capital Management Gold Quality", and 8 companies that were recognized by experts as having made particularly outstanding efforts were selected as "Human Capital Leaders 2023" out of approximately 500 participating companies and organizations.
  • Moreover, Eisai published the "Human Capital Report 2023" (PDF) in July, 2023 that summarizes its human capital initiatives and KPI linked to its human resource strategies.
  • Eisai promotes information disclosure regarding its initiatives on human capital management in its annual "Value Creation Report(PDF)" and on its corporate website's "Sustainability" section.

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

Retrieved on: 
金曜日, 2月 16, 2024

TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).

Key Points: 
  • TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
  • Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
  • This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection.
  • The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin).

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa

Retrieved on: 
木曜日, 2月 1, 2024

Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya

Key Points: 
  • Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya
    TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd ("Eisai South Africa"), a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
  • Eisai South Africa is a wholly-owned subsidiary of Eisai.
  • Eisai South Africa has started sales and marketing activities directly for Lenvima and Fycompa from January 2024, as well as Halaven from February 2024.
  • Seeking solutions to these challenges in Africa, Eisai will continue its initiatives to deliver necessary medicines to the patients who need them through Eisai South Africa and Eisai Kenya.

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis

Retrieved on: 
金曜日, 1月 26, 2024

TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.

Key Points: 
  • TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
  • In May 2022, ultrahigh-dose mecobalamin received orphan drug designation by the Ministry of Health, Labour and Welfare (MHLW).
  • The results of JETALS were published in the peer-reviewed journal JAMA Neurology.
  • ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction.

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan

Retrieved on: 
木曜日, 1月 18, 2024

TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Key Points: 
  • TOKYO, Jan 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
  • Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and filed a supplementary new drug application as a new route of administration in August 2022, leading to this approval.